Population pharmacokinetics of human antithrombin concentrate in paediatric patients
暂无分享,去创建一个
J. Teruya | D. Mahoney | B. Moffett | M. Galati | D. Yee | R. Díaz
[1] V. Felix,et al. A single center experience , 2019 .
[2] D. Mahoney,et al. Antithrombin Concentrate Use in Children Receiving Unfractionated Heparin for Acute Thrombosis. , 2015, The Journal of pediatrics.
[3] A. Reiner,et al. Antithrombin Concentrates Use in Children on Extracorporeal Membrane Oxygenation: A Retrospective Cohort Study , 2015, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[4] S. Kuhle,et al. Antithrombin Concentrate in Pediatric Patients Requiring Unfractionated Heparin Anticoagulation: A Retrospective Cohort Study* , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[5] U. Dyamenahalli,et al. Antithrombin III Supplementation on Extracorporeal Membrane Oxygenation: Impact on Heparin Dose and Circuit Life , 2014, ASAIO journal.
[6] P. Seksarn,et al. Reference values for thrombotic markers in children , 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[7] S. Vesely,et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[8] J. Tweddell,et al. Antithrombin replacement during extracorporeal membrane oxygenation. , 2011, Artificial organs.
[9] Mats O. Karlsson,et al. Approaches to handling pharmacodynamic baseline responses , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[10] G. Guyatt,et al. Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .
[11] J. Svennevig,et al. Evaluation of oxygenators and centrifugal pumps for long-term pediatric extracorporeal membrane oxygenation , 2007, Perfusion.
[12] S. S. St. Peter,et al. The initial experience of antithrombin III in the management of neonates with necrotizing enterocolitis. , 2007, Journal of pediatric surgery.
[13] M. Aibiki,et al. SERUM ALBUMIN LEVELS ANTICIPATE ANTITHROMBIN III ACTIVITIES BEFORE AND AFTER ANTITHROMBIN III AGENT IN CRITICAL PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION , 2007, Shock.
[14] B. Schmidt,et al. Antithrombin for respiratory distress syndrome in preterm infants. , 2006, The Cochrane database of systematic reviews.
[15] A. Ündar,et al. Use of a Novel Anticoagulation Strategy During ECMO in a Pediatric Population: Single-Center Experience. , 2006, ASAIO journal.
[16] A. Spitzer,et al. Reported Medication Use in the Neonatal Intensive Care Unit: Data From a Large National Data Set , 2006, Pediatrics.
[17] B. Schmidt,et al. Antithrombin replacement in neonates: is there any indication? , 2006, Thrombosis research.
[18] U. Desai,et al. Roles of N-terminal region residues Lys11, Arg13, and Arg24 of antithrombin in heparin recognition and in promotion and stabilization of the heparin-induced conformational change. , 2004, Biochemistry.
[19] U. Desai,et al. Antithrombin III Phenylalanines 122 and 121 Contribute to Its High Affinity for Heparin and Its Conformational Activation* , 2003, The Journal of Biological Chemistry.
[20] A. Marzo,et al. Pharmacokinetic Behaviour of Antithrombin III Following Intravenous Infusion in Healthy Volunteers , 2002, Arzneimittelforschung.
[21] A. Suminoe,et al. ANTITHROMBIN III SUPPLEMENTATION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH L-ASPARAGINASE , 2002 .
[22] A. Suminoe,et al. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase. , 2002, Pediatric Hematology & Oncology.
[23] V. Fuster,et al. Mechanism of action and pharmacology of unfractionated heparin. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[24] J. Decruyenaere,et al. Antithrombin III in patients with severe sepsis: a pharmacokinetic study , 2000, Intensive Care Medicine.
[25] U. Bürger,et al. Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters. , 1997, Biology of the neonate.
[26] U. Pendurthi,et al. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. , 1995, Blood.